Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Mei Pharma Inc (MEIP)
Mei Pharma Inc (MEIP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,984
  • Shares Outstanding, K 6,663
  • Annual Sales, $ 48,820 K
  • Annual Income, $ -31,840 K
  • 60-Month Beta 0.81
  • Price/Sales 0.57
  • Price/Cash Flow N/A
  • Price/Book 0.48
Trade MEIP with:

Options Overview Details

View History
  • Implied Volatility 13.29% ( -1.76%)
  • Historical Volatility 45.01%
  • IV Percentile 23%
  • IV Rank 1.18%
  • IV High 1,103.14% on 03/20/23
  • IV Low 0.24% on 12/27/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 3
  • Volume Avg (30-Day) 64
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 1,323
  • Open Int (30-Day) 797

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.38
  • Number of Estimates 2
  • High Estimate -1.34
  • Low Estimate -1.42
  • Prior Year -2.32
  • Growth Rate Est. (year over year) +40.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.13 +0.48%
on 02/29/24
4.97 -16.50%
on 02/12/24
-0.39 (-8.59%)
since 01/29/24
3-Month
4.13 +0.48%
on 02/29/24
6.91 -39.94%
on 12/07/23
-1.97 (-32.19%)
since 11/29/23
52-Week
4.13 +0.48%
on 02/29/24
7.97 -47.93%
on 05/23/23
-0.29 (-6.62%)
since 02/28/23

Most Recent Stories

More News
Assertio (ASRT) Reports Q1 Loss, Tops Revenue Estimates

Assertio (ASRT) delivered earnings and revenue surprises of -153.85% and 12.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ASRT : 0.8839 (+4.33%)
MEIP : 4.15 (-1.19%)
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 11.11% and 24.64%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

TBPH : 9.47 (+0.74%)
MEIP : 4.15 (-1.19%)
MEI Pharma Announces 1-for-20 Reverse Stock Split

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that its board of directors approved a 1-for-20 reverse stock split....

MEIP : 4.15 (-1.19%)
SHAREHOLDER ALERT: Weiss Law Investigates Infinity Pharmaceuticals, Inc.

/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Infinity...

INFI : 0.0080 (-50.00%)
MEIP : 4.15 (-1.19%)
INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Infinity Pharmaceuticals, Inc. (the “Company”)...

INFI : 0.0080 (-50.00%)
MEIP : 4.15 (-1.19%)
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Infinity Pharmaceuticals, Inc.

/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and its board of...

INFI : 0.0080 (-50.00%)
MEIP : 4.15 (-1.19%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNKB, PTRS, JNCE, MEIP

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

LNKB : 6.88 (+3.15%)
PTRS : 7.15 (+0.99%)
JNCE : 1.8800 (-2.59%)
MEIP : 4.15 (-1.19%)
MEIP STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of MEI Pharma, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of MEI Pharma, Inc. (NASDAQ: MEIP) and Infinity Pharmaceuticals, Inc. is fair to MEI shareholders. Per the merger agreement,...

MEIP : 4.15 (-1.19%)
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates

MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a...

MEIP : 4.15 (-1.19%)
INFI : 0.0080 (-50.00%)
MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 150% and 237.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

MEIP : 4.15 (-1.19%)
COLL : 36.71 (+0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards,...

See More

Key Turning Points

3rd Resistance Point 4.46
2nd Resistance Point 4.39
1st Resistance Point 4.27
Last Price 4.15
1st Support Level 4.08
2nd Support Level 4.01
3rd Support Level 3.89

See More

52-Week High 7.97
Fibonacci 61.8% 6.50
Fibonacci 50% 6.05
Fibonacci 38.2% 5.60
Last Price 4.15
52-Week Low 4.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar